http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression
-
Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression
-
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
-
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
-
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
-
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
-
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
-
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Gilead Sciences (GILD), Scholar Rock (SRRK) Announce Pact to Develop Novel Therapies for Fibrotic Diseases
-
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases
-
Scholar Rock Holding Corp. (SRRK) Announces Positive Opinion by EMA on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
-
Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
-
Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
-
Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
-
Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
-
Scholar Rock Holding Corp. (SRRK) Reports Publication of Preclinical Data on Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
-
Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
-
Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
-
Scholar Rock Holding Corp. (SRRK) Appoints Edward (Ted) Myles to Board
-
Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
-
Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
-
Scholar Rock Holding Corp. (SRRK) Reports New Preclinical Data from TGFB1 Cancer Immunotherapy Program
-
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade
-
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade
